Healthcare and life sciences executive Stacy Chick is the chief commercial officer of Inivata, Inc. In her role at the molecular oncology diagnostics firm, Stacy Chick leads product sales, marketing, and commercialization efforts. She was part of the team that delivered the collaboration between Inivata and NeoGenomics, Inc.
On May 26, 2020, Inivata announced a strategic partnership with NeoGenomics, a leading cancer diagnostics and services company, for the commercialization the of InVisionFirst(R) Lung liquid biopsy test. NeoGenomics can rapidly deploy InVisionFirst(R) Lung across its network, helping patients with lung cancer who need highly sensitive liquid biopsy tests within a short time.
NeoGenomics will also initiate opportunities for collaboration between Inivata and biopharmaceutical companies. Additionally, NeoGenomics will accelerate the rolling out of other Inivata products, such as the recently launched RaDar for detecting residual disease and recurrence.
NeoGenomics will invest $25 million in Inivata, taking a minority equity stake with the option of buying the company as a whole. The investment will be used to accelerate Inivata’s pipeline of liquid biopsy products.
